ClinicalTrials.gg
CompletedNCT01022424Updated Sep 11, 2018Results posted

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

A Phase 3 interventional study of OPC-41061 in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
18th of 18
13 · median 91
Started
2009
the only one that year
Phase 3
8 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
3 of 18
Otsuka Pharmaceutical Co., Ltd.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 18th largest by enrollment, is the only one that started in 2009, is one of 8 in phase 3, and was the 4th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • ADPKD
  • Tolvaptan
  • OPC-41061
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)
  • Patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.

Exclusion criteria

Exclusion Criteria:

  • Patients with of less than 15 mL/min/1.73 m2
  • Patients with any of the following complications:

    • Uncontrolled hypertension
    • Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)
  • Patients with any of the following complications or history thereof:

    • drug allergies (anaphylaxis) or (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity
    • Inability to personally give consent due to a mental illness
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    OPC-41061

    Repeated oral administration at doses of 15 mg twice daily (morning and evening)

    Drug: OPC-41061

Interventions

  • Repeated oral administration at doses of 15 mg twice daily (morning and evening)

06

What researchers measure

Primary outcomes

  1. Total Kidney Volume

    Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period. Repeated oral administration at doses of 15 mg twice daily (morning and evening) until approval of the revised protocol (Edition 4.0) by the IRB of each trial site. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, Week 48, 96, 144, and 192

  2. Renal Function Test (eGFR)

    Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, Week 48, 96, 144, and 192

07

Results

Posted Jul 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061
Started13
Completed9
Not completed4
Withdrew: Adverse event1
Withdrew: Physician decision1
Withdrew: Egfr under the withdrawal criteria2

Outcome measures

PrimaryTotal Kidney Volume

Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period. Repeated oral administration at doses of 15 mg twice daily (morning and evening) until approval of the revised protocol (Edition 4.0) by the IRB of each trial site. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, Week 48, 96, 144, and 192
Reported as:
Median · mL
Total Kidney Volume
mLBaselineWeek 48Week 96Week 144Week 192
Total Kidney Volume1428 (789 to 4774)1675 (786 to 4457)1728 (791 to 4193)1775 (818 to 4125)1901 (837 to 3669)
PrimaryRenal Function Test (eGFR)

Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, Week 48, 96, 144, and 192
Reported as:
Median · mL/min/1.73 m2
Renal Function Test (eGFR)
mL/min/1.73 m2BaselineWeek 48Week 96Week 144Week 192
Renal Function Test (eGFR)63.0 (31.0 to 93.0)60.0 (23.0 to 92.0)54.0 (22.0 to 113.0)50.5 (15.0 to 63.0)51.0 (16.0 to 64.0)

Adverse events

Collected over Through study completion, an average of 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-410610/13 (0%)6/13 (46.2%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventOPC-41061
Retinal vein occlusionEye disorders1/13
Abdominal painGastrointestinal disorders1/13
Large intestine polypGastrointestinal disorders1/13
PyrexiaGeneral disorders1/13
Hepatic cyst infectionInfections and infestations1/13
PyelonephritisInfections and infestations1/13
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/13
AlcoholismPsychiatric disorders1/13
HypertensionVascular disorders1/13
Most frequent other events
Showing 10 of 114
Most frequent other events
EventOPC-41061
NasopharyngitisInfections and infestations8/13
Blood antidiuretic hormone increasedInvestigations7/13
HypertensionVascular disorders7/13
ThirstGeneral disorders6/13
Back painMusculoskeletal and connective tissue disorders5/13
HyperuricaemiaMetabolism and nutrition disorders4/13
HeadacheNervous system disorders4/13
PollakiuriaRenal and urinary disorders4/13
PyrexiaGeneral disorders3/13
PolyuriaRenal and urinary disorders3/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OPC-41061
<=18 years0
Between 18 and 65 years13
>=65 years0
Age, Continuous
Age, Continuous(years)OPC-41061
Mean45.6 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061
Female6
Male7
Region of Enrollment
Region of Enrollment(participants)OPC-41061
Japan13
08

Study locations

1 site
  • Kanto Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2009
First posted
Dec 1, 2009
Start
Nov 2009
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Jul 27, 2018
Last update
Sep 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01022424
Responsible party
Sponsor
First posted
Dec 1, 2009
Start date
Nov 2009
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Jul 27, 2018
Last update
Sep 11, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion